Skip to main content

Pemitinib 13.5 mg ( Pemigatinib)

General Information

The information published on Pemitinib.com is provided for general educational and informational purposes.

This website discusses Pemitinib 13.5 mg, identified as a product containing pemigatinib, an oral targeted anticancer medicine belonging to the fibroblast growth factor receptor inhibitor class.

The content may include information about the medicine’s active ingredient, pharmacological classification, recognized medical uses, general dosage schedules, administration, possible adverse reactions, safety precautions and product information.

Although care is taken to present information clearly, website content should not be interpreted as a substitute for professional medical advice, diagnosis, prescribing information or treatment.

Not a Substitute for Medical Advice

Information on Pemitinib.com does not establish a doctor-patient relationship.

The website does not provide individualized diagnosis, treatment recommendations, medical prescriptions or clinical consultations.

Every patient’s medical circumstances are different.

A qualified healthcare professional must assess the patient’s diagnosis, medical history, test results, previous treatments, current medicines and overall health before making treatment decisions.

Patients should not begin, stop, change or interrupt pemigatinib treatment based only on information published on this website.

Prescription Medicine Warning

Pemigatinib is a prescription anticancer medicine.

Its use requires an appropriate medical indication, specialist supervision and regular monitoring.

Patients should only use a pemigatinib-containing product when it has been prescribed by a qualified healthcare professional and obtained through an appropriate pharmaceutical supply channel.

Using prescription anticancer medicines without medical supervision may expose patients to serious health risks.

Accuracy of Medicine Information

We aim to present information about pemigatinib using appropriate pharmaceutical terminology and established prescribing information.

However, medical knowledge, product labeling and regulatory requirements may change over time.

Information may also differ between countries because regulatory authorities can approve different indications, restrictions and product instructions.

Visitors should consult the latest official prescribing information applicable to their country and the specific product they are using.

Product Identity and Manufacturer Information

Pemitinib is identified on this website as a product containing pemigatinib 13.5 mg.

The information about pemigatinib and its established reference brand PEMAZYRE should not be treated as independent verification of every Pemitinib product detail.

The specific manufacturer, brand owner, marketing authorization holder, packaging, regulatory status and manufacturing location of Pemitinib require product-specific confirmation.

Pemitinib.com does not guarantee the authenticity, quality, availability or regulatory authorization of a particular package.

Dosage and Administration Disclaimer

Dosage information presented on this website is intended to explain general prescribing principles.

The U.S. reference-product schedule for qualifying cholangiocarcinoma is 13.5 mg once daily for 14 consecutive days followed by seven days without treatment.

The U.S. labeled schedule for qualifying FGFR1-rearranged myeloid/lymphoid neoplasms is 13.5 mg once daily continuously.

These schedules are different and are not interchangeable.

Actual dosing decisions must be made by the treating healthcare professional according to the relevant diagnosis, prescribing information, patient condition and treatment response.

Side Effects and Safety Disclaimer

The website may describe common and serious adverse reactions associated with pemigatinib.

However, this information does not predict exactly which adverse reactions an individual patient will experience.

Some reactions may require immediate medical assessment.

Important risks associated with pemigatinib include hyperphosphatemia and ocular toxicity, including retinal pigment epithelial detachment.

Patients should report new or worsening symptoms to their treating healthcare professional.

For severe symptoms or medical emergencies, seek immediate medical attention rather than relying on website information.

Pregnancy and Reproductive Health

Pemigatinib may cause fetal harm.

Patients who are pregnant, planning pregnancy, breastfeeding or concerned about reproductive health should discuss the risks with their healthcare professional before treatment.

The U.S. reference-product prescribing information provides contraception recommendations for females of reproductive potential during treatment and for one week after the final dose.

Patients should consult the applicable product information and treating specialist for complete reproductive safety guidance.

Drug Interactions

Medicines, supplements and certain foods may affect how prescription medicines work.

Pemigatinib can interact with medicines that affect CYP3A enzymes.

Visitors should not use website information to independently start, stop or change another medicine.

A doctor or pharmacist should review the patient’s complete medication list before treatment and whenever a new medicine is introduced.

No Guarantee of Treatment Results

Pemitinib.com does not guarantee that pemigatinib will produce a particular clinical outcome.

Treatment response varies between patients and depends on several factors, including:

  • Cancer type and molecular characteristics.
  • Disease stage.
  • Previous treatment.
  • Overall health.
  • Treatment tolerance.
  • Adverse reactions.
  • Individual biological factors.

The presence of a qualifying genetic abnormality does not guarantee a specific response.

External Information and Regulatory Differences

Prescription medicine information may vary between jurisdictions.

A treatment indication approved in one country may not be approved in another.

Patients and healthcare professionals should use the prescribing information applicable to their location and product.

The website does not guarantee that every statement reflects the latest regulatory position in every country.

Limitation of Responsibility

Pemitinib.com is intended as an educational information resource.

Visitors remain responsible for obtaining appropriate medical advice and verifying medicine information with qualified professionals.

Nothing on this website should be interpreted as a guarantee of product authenticity, treatment effectiveness, medicine availability or regulatory authorization.

Emergency Medical Situations

Do not rely on Pemitinib.com for emergency medical advice.

If a patient experiences severe symptoms, sudden visual changes, signs of a serious allergic reaction or another urgent medical problem, seek immediate medical attention.

Acceptance of This Disclaimer

By using Pemitinib.com, visitors acknowledge that the website provides general educational information and does not replace professional medical care.

Readers should consult qualified healthcare professionals before making decisions involving pemigatinib or any other prescription medicine.